NCT01850056

Brief Summary

The purpose of this study is to determine whether DEB is more effective than common PTA balloon in long-term vessel patency and inhibiting restenosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2013

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

April 27, 2013

Completed
12 days until next milestone

First Posted

Study publicly available on registry

May 9, 2013

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2016

Completed
Last Updated

July 12, 2018

Status Verified

December 1, 2015

Enrollment Period

3.3 years

First QC Date

April 27, 2013

Last Update Submit

July 11, 2018

Conditions

Keywords

drug eluting balloon catheter

Outcome Measures

Primary Outcomes (1)

  • Late Lumen Loss

    measure difference of the MLD(minimal lumen diameter) at 0 time and 6 months

    6 months

Secondary Outcomes (7)

  • Minimal lumen diameter (MLD)

    6 months

  • Restenosis rate of target vessel

    6 months, 12 months, 18 months, 24months

  • target lesion revascularization

    6 months, 12 months, 18 months, 24 months

  • change in Rutherford stage

    6 months, 12 months, 18 months, 24 months

  • change in ankle brachial index(ABI)

    6 months

  • +2 more secondary outcomes

Study Arms (2)

drug eluting balloon catheter

EXPERIMENTAL

use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery

Device: drug eluting balloon catheter (trade name: Orchid)

common balloon catheter(uncoated drug)

ACTIVE COMPARATOR

use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery

Device: common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)

Interventions

Also known as: drug eluting dilation catheter
drug eluting balloon catheter
Also known as: common PTA catheter
common balloon catheter(uncoated drug)

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 18 and 80 years
  • Patients with peripheral artery disease (PAD), with Rutherford classification between 2 and 5
  • an occlusion or a minimum grade of stenosisPrimary over 70% in the superficial femoral artery an /or the popliteal artery
  • Total length of treat lesion(s)is less or equal to 40cm
  • signed Patient informed consent form

You may not qualify if:

  • plasma Cr level greater than 150 umol/L in patients
  • patients with acute thrombosis requiring lysis or thrombectomy
  • patient with a lysis or an lower limb intervention as a therapy within the last 6 weeks
  • patient requiring intervention in both lower limbs at the same time
  • target lesion can't be cross by the guide wire
  • distal outflow through less than one lower leg vessel
  • known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium, etc.
  • patients participating in another clinical trials with interfere with this trial in the past 3 months
  • pregnancy and lactating woman
  • untreatable bleeding diatheses
  • other diseases, such as cancer, liver disease, or cardiac insufficiency, which may lead to protocol violations or markedly shorten a patients's life expectancy(less than 2 years)
  • patients unable or unwilling to participate this trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Xiyuan Hospital CACMS

Beijing, Beijing Municipality, 100091, China

Location

Chinese PLA General Hospital

Beijing, Beijing Municipality, 100853, China

Location

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Location

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

Location

The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

Location

The second Hospital Of Hebei University

Shijiazhuang, Hebei, 050000, China

Location

The First Affiliated Hospital, Dalian Medical University

Dalian, Liaoning, China

Location

The People's Hospital of Liaoning Province

Shenyang, Liaoning, China

Location

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, 200032, China

Location

Renji Hospital ShangHai Jiaotong University School Of Medicine

Shanghai, Shanghai Municipality, China

Location

Related Publications (2)

  • Ren H, Liu J, Zhang J, Zhuang B, Fu W, Wu D, Wang F, Zhao Y, Guo P, Bi W, Wang S, Guo W. Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease. Int J Gen Med. 2021 Aug 5;14:4197-4207. doi: 10.2147/IJGM.S316916. eCollection 2021.

  • Sun G, Liu J, Jia S, Zhang J, Zhuang B, Jia X, Fu W, Wu D, Wang F, Zhao Y, Guo P, Bi W, Wang S, Guo W; AcoArt I Trial Investigators. Comparison of drug-coated balloon angioplasty versus uncoated balloon angioplasty in treatment of total occlusions with severe femoropopliteal lesions: An additional analysis from the AcoArt I study. Vascular. 2021 Jun;29(3):340-349. doi: 10.1177/1708538120953663. Epub 2020 Sep 9.

MeSH Terms

Conditions

Peripheral Arterial Disease

Condition Hierarchy (Ancestors)

AtherosclerosisArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesPeripheral Vascular Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 27, 2013

First Posted

May 9, 2013

Study Start

April 1, 2013

Primary Completion

August 1, 2016

Study Completion

September 1, 2016

Last Updated

July 12, 2018

Record last verified: 2015-12

Locations